Relief Therapeutics Holding AG (RLFTF)

[changes_iv]

Well, we are back on that horse again. I read...For pulmonary sarcoidosis, the initiation dosage is 20 to 40 mg per day of prednisone or its equivalent for one to three months. Every-otherday dosing also may be considered. In patients who respond, the prednisone dose should be tapered to 5 to 10 mg per day or every other day for a minimum of 12 months.

https://www.aafp.org/afp/2004/0715/p312.html
CRIPPLING...
Sarcoidosis is a systemic granulomatous disease of unknown cause affecting young and middle-aged adults. Patients commonly present with bilateral hilar lymphadenopathy, pulmonary infiltrates, and ocular and skin lesions. The heart, liver, spleen, salivary glands, muscles, bones, kidneys, and central nervous system also may be involved.

https://www.aafp.org/afp/2004/0715/p312.html

AND VIP??? Inhaled Vasoactive Intestinal Peptide Exerts Immunoregulatory Effects in Sarcoidosis =================

Rationale: Previous studies suggest an important immunoregulatory role of vasoactive intestinal peptide (VIP) in experimental models of chronic noninfectious inflammation. Sarcoidosis is characterized by noncaseating epitheloid cell granulomas, where excessive tumor necrosis factor-a production by pulmonary macrophages plays a critical role in granuloma formation and disease progression, which may lead to fatal organ dysfunction.

———— Objectives: To test whether inhaled VIP has an immunoregulatory role. Sarcoid alveolitis was used as a prototype of immune-mediated chronic lung inflammation. —————————-

Conclusions: This study is the first to show the immunoregulatory effect of VIP in humans, and supports the notion of inhaled VIP as an attractive future therapy to dampen exaggerated immune responses in lung disorders. Thus, the inhalation of neuropeptides may be developed into a new therapeutic principle for chronic inflammatory lung disorders in humans.

https://www.atsjournals.org/doi/full/10.1164/rccm.200909-1451OC